# Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations

> **NCT05445791** · PHASE3 · RECRUITING · sponsor: **Instituto Nacional de Cancerologia de Mexico** · enrollment: 312 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Metformin Hydrochloride
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05445791
- **Lead sponsor:** Instituto Nacional de Cancerologia de Mexico
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-15
- **Primary completion:** 2026-07-14
- **Final completion:** 2027-07-14
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445791, "Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05445791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*